Printer Friendly

Articles from Contract Pharma (June 1, 2016)

1-83 out of 83 article(s)
Title Author Type Words
17th Annual $alary $urvey. 972
1Q R&D for pharma & biopharma. 175
2016 BIO Convention heads to San Francisco: annual convention brings together more than 15,000 pharma and biopharma leaders. 969
2016 Contracting and Outsourcing Conference & Tabletop Exhibition. Calendar 618
3M unveils Intelligent inhaler. 292
A Mars/Venus perspective on sponsor/contractor relationships: aligning the planets for shared quality responsibilities. Neway, Justin 2113
AbbVie, CytomX Therapeutics. 360
Alcami expands capabilities at four U.S. sites. 201
Alectos Therapeutics was granted orphan drug designation for OGA inhibitor MK-8719 for the treatment of progressive supranuclear palsy (PSP). 165
Allergan. 153
Almac launches U.S. serialization capabilities. 269
AMRI acquires Euticals for $358m. 286
AMRI. 229
Anti-counterfeiting in the pharmaceutical industry: an evolution: keeping up with counterfeitors in the pharmaceutical industry is no easy task, but patients' lives depend on it. Locwin, Ben 711
Aptar Pharma launches eDose Counter. 227
Aptuit acquires Kuecept. 190
Are more CRO transactions near? When will we see additional transactions involving the largest CROs? Moore, Chad 758
Astellas. 186
Betting big on injectables: firms hone skills and boost capacities. Harachand, S. 778
Bioclinica, ArisGlobal partner on Pharmacovigilance Services. 156
Biogen to spin off hemophilia business. 583
Biogen. 217
Biopharma CMO market trends: all signs point to continued strong growth in the biologies segment driven by robust development pipelines, increased drug approvals, the rise of biosimilars and incentives to go after neglected or unmet medical needs. Wright, Tim 2012
Biotech boom fuels parental market: assessing the trends driving parenteral manufacturing. MacKay, Colin 1594
Bosch expands downstream portfolio for syringes. 322
Brammer Bio formed through merger: Brammer Biopharmaceuticals and Florida Biologix have joined forces to create a leading cell and gene therapy CDMO. Wright, Tim Interview 1549
Bristol-Myers Squibb and AbbVie received approval from the European Commission for Emplicit (elotuzumab) for the treatment of multiple myeloma as combination therapy with Revlimid (lenalidomide) and dexamethasone in patients who have received at least one prior therapy. 221
Caladrius Biosciences' CLBS03 (autologous expanded polyclonal regulatory T cells, or Tregs) candidate for the treatment of recent-onset type 1 diabetes (T1D) was granted orphan-drug designation by the U.S. FDA for the treatment of type 1 diabetes mellitus with residual beta cell function. 206
Charles River Laboratories. 119
China vaults to the top of U.S. biomanufacturers' off-shoring prospects: a look at top destinations for future offshoring. Langer, Eric S. 1998
Clinical manufacturing on time and within budget: simplifying the drug development process. Brett, David 2478
Company showcase. 2556
Continuous granulation technology trends: seeking a smooth path and avoiding dead ends. Parikh, Dilip M. 2373
Contract packaging market trends: contract packagers talk about hot growth areas and the looming 2017 DSCSA deadline. Wright, Tim 2202
Contract Pharmacal Corp. 126
CRO revenues are being jeopardized by calls not connecting: in the current economic climate, CROs are increasingly turning to Unified Communications (UC) solutions to drive collaboration between patients, hospitals, staff, and doctors. Levenson, Stephen 658
DCAT sharp sourcing 2016: keep up with the latest sourcing and procurement trends July 12 in New Brunswick, NJ. Interview 715
Developments in orphan drug exclusivity after Depomed: a look at FDA's reaction to and future implications of the recent court decision in Depomed vs. U.S. Dept. of Health and Human Services. Lubit, Beverly W. 2144
EMD Millipore launches cancer stem cell identification kit. 214
EMD Serono expands Billerica biopharma facility. 206
Five Prime Therapeutics has advanced FPA008 into the Phase II dose expansion portion of the ongoing Phase 1/2 trial in PigmentedVillonodular Synovitis (PVNS). 186
Fujifilm Diosynth opens new lab. 160
Generic Specialties acquires Axcellerate Pharma. 229
Gilead. 132
Healthcare companies tackle supply chain issues: UPS study shows logistics gains in some areas, challenges in others. Denecker, Jan 1097
How 'mush-room' for improvement in antibiotic production? The medical world is acutely aware of the issues on the horizon with regards to antibiotic resistance. Graham-King, Adele 814
Improving packaging processes to meet regulatory and patient needs: while the market is demanding safe, effective and affordable drugs, contract service providers are turning to advanced automation and packaging technologies to deliver them. Bray, John 1779
IMS Health, Quintiles to merge. 317
Industry events. Calendar 373
Innopharma Technology, Glatt in strategic mfg. pact: to incorporate PAT solutions into fluid bed and continuous process equipment. 246
Is the industry rising to the challenge of serialization? A look at what you should be doing to overcome the obstacles to implementation. Widengren, Staffan 1352
Johnson & Johnson. 134
Limiting APIs in manufacturing effluent: an approach for setting limits on pharmaceuticals discharged in manufacturing effluent. Tell, Joan; Drinane, Robert; Naumann, Bruce; Vestel, Jessica; Gagliano, Gregory 2781
Lonza. 113
Marinus Pharmaceuticals was granted Orphan Drug Designation by the FDA for the intravenous (IV) formulation of its CNS-selective GABAA modulator, ganaxolone, for the treatment of status epilepticus. 104
Marken adds service providers to global network. 216
Merck's KEYTRUDA (pembrolizumab), an anti-PD-1 therapy for the treatment of relapsed or refractory classical Hodgkin lymphoma (cHL), has been granted Breakthrough Therapy Designation by the FDA. 115
Merck. 154
MilliporeSigma to expand Carlsbad facility. 137
Novartis was granted three Breakthrough Therapy Designations by the FDA for Ilaris (canakinumab) to treat three rare types of Periodic Fever Syndromes, also known as Hereditary Periodic Fevers. 185
Pall launches Allegro STR 1000 bioreactor. 207
Partnering for success: opportunity abounds for contract service providers in the robust biopharma market. Wright, Tim 402
Pfizer achieved positive results from two Phase III studies demonstrating the immunogenicity of TRUMENBA (Meningococcal Group B Vaccine) against invasive meningococcal B (MnB) strains representative of prevalent strains in the U.S. and Europe. 200
Pfizer revenues jump 20%. 166
Pfizer to acquire Anacor. 305
Pharma Tech Industries. 222
PPD expands Asia-Pac communications. 122
Product highlights from INTERPHEX 2016. 1193
Recro acquires Alkermes Mfg. site in GA. 137
Regeneron Pharmaceuticals achieved positive results from a placebo-controlled Phase II/III study evaluating fasinumab in patients with moderate-to-severe osteoarthritis pain of the hip or knee who have a history of inadequate pain relief or intolerance to current analgesic therapies. Clinical report 190
REGENXBIO, Biogen. 281
Renaissance to divest topical biz to Mylan. 223
Skyepharma chooses MG2's Planeta. 257
Stellar Biotechnologies, Neovacs. 460
Sterigenics expands Germany location. 122
Successful method transfer of solid oral dosage: the three steps outlined will help guide the process of completing a successful analytical method transfer. Frankonis, John 1453
Takeda. 174
The four stages of networking: in the networking trenches, making business connections isn't all about business. Jensen, David G. 1463
Turning a cost center into a cash cow: a superior analytical lab is an asset, not overhead cost. Ciurczak, Emil W. 1542
Valeant names chairman, CEO. 135
Who's the right service provider for you? Factors to consider when choosing between using one integrated CDMO or a series of smaller functional service providers. Peck, Raymond 1384
Zenith Technologies. 252
Zenith, Werum IT. 248

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters